Corporate Overview
Biomea Fusion (NASDAQ: BMEA) is a U.S. based clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. We believe that we have found a method to reverse the root cause of diabetes leading to reduced dependency on life-long chronic therapy.
Our lead development candidate, icovamenib, is positioned to be the first disease modifying treatment for diabetes. Icovamenib inhibits menin, which thereby promotes restoration of insulin-producing beta cells, which are depleted by approximately 50% at the time of diagnosis of Type 2 Diabetes.1 The functional restoration of this replenished pool of beta cells can potentially provide significant glycemic benefits for diabetes patients. Icovamenib's mechanism has also shown synergistic effects when combined with a GLP-1-based therapy, allowing for enhanced efficacy in glycemic management and weight reduction, additionally paired with preservation of lean muscle mass.
Our second development candidate, BMF-650, is a next-generation oral GLP-1 receptor agonist similar to the Chugai/orforglipron chemotype class, optimized for improved properties and projected to enter clinical studies in the second half of 2025.
With our programs, we are focused on addressing metabolic disorders, a public health concern impacting approximately 50% of Americans and 20% of the world's population.
Visit us at biomeafusion.com and follow us on LinkedIn, Twitter and Facebook.
Stock Quote
Minimum 15 minutes delayed. Source: LSEG